News
-
-
PRESS RELEASE
Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report
Sanofi files amendment to French 'Document d’Enregistrement Universel' with annual financial report, including governance updates. Available on Sanofi and AMF websites -
-
PRESS RELEASE
Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment. Positive CHMP opinion based on clinical studies -
-
PRESS RELEASE
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis
Sanofi and Regeneron's Dupixent approved in the US as the first medicine for allergic fungal rhinosinusitis, supported by phase 3 study. A breakthrough in treating chronic sinus disease -
-
-
-
PRESS RELEASE
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease
Sanofi and Teva's duvakitug phase 2b maintenance data show durable efficacy in ulcerative colitis and Crohn's disease. Results reinforce ongoing phase 3 programs in UC and CD
